Shares of Allscripts Healthcare Solutions Inc. (NASDAQ:MDRX) have earned a consensus rating of “Hold” from the twenty brokerages that are covering the firm. Eleven research analysts have rated the stock with a hold recommendation and nine have issued a buy recommendation on the company. The average 1 year price target among brokers that have covered the stock in the last year is $15.31.
A number of analysts recently weighed in on the company. JPMorgan Chase & Co. assumed coverage on Allscripts Healthcare Solutions in a research report on Sunday, October 30th. They issued a “buy” rating and a $15.00 target price for the company. Canaccord Genuity set a $17.00 price target on Allscripts Healthcare Solutions and gave the stock a “buy” rating in a research note on Saturday, November 19th. Piper Jaffray Cos. reaffirmed a “neutral” rating and issued a $15.00 price target (up from $12.00) on shares of Allscripts Healthcare Solutions in a research note on Monday, August 8th. Zacks Investment Research raised Allscripts Healthcare Solutions from a “hold” rating to a “buy” rating and set a $16.00 price target on the stock in a research note on Tuesday, August 9th. Finally, Goldman Sachs Group Inc. lifted their price target on Allscripts Healthcare Solutions from $14.00 to $16.00 and gave the stock a “neutral” rating in a research note on Friday, August 5th.
In other Allscripts Healthcare Solutions news, CEO Paul Black sold 15,000 shares of the stock in a transaction dated Thursday, September 15th. The stock was sold at an average price of $13.00, for a total value of $195,000.00. Following the transaction, the chief executive officer now owns 1,177,009 shares of the company’s stock, valued at $15,301,117. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, SVP James Hewitt sold 17,500 shares of the stock in a transaction dated Thursday, September 15th. The shares were sold at an average price of $13.00, for a total value of $227,500.00. Following the completion of the transaction, the senior vice president now directly owns 158,104 shares in the company, valued at approximately $2,055,352. The disclosure for this sale can be found here. Insiders own 0.75% of the company’s stock.
A number of hedge funds and other institutional investors have recently bought and sold shares of MDRX. Nuveen Asset Management LLC increased its position in Allscripts Healthcare Solutions by 82.1% in the first quarter. Nuveen Asset Management LLC now owns 139,737 shares of the company’s stock worth $1,846,000 after buying an additional 63,000 shares in the last quarter. Seven Eight Capital LLC purchased a new position in Allscripts Healthcare Solutions during the first quarter worth $102,000. Teacher Retirement System of Texas increased its position in Allscripts Healthcare Solutions by 13.8% in the second quarter. Teacher Retirement System of Texas now owns 25,127 shares of the company’s stock worth $319,000 after buying an additional 3,041 shares in the last quarter. First Quadrant L P CA increased its position in Allscripts Healthcare Solutions by 473.4% in the second quarter. First Quadrant L P CA now owns 71,100 shares of the company’s stock worth $903,000 after buying an additional 58,700 shares in the last quarter. Finally, Fox Run Management L.L.C. purchased a new position in Allscripts Healthcare Solutions during the second quarter worth $182,000.
Allscripts Healthcare Solutions (NASDAQ:MDRX) traded up 0.27% during trading on Friday, hitting $11.19. The company’s stock had a trading volume of 785,719 shares. The firm has a 50 day moving average of $11.82 and a 200 day moving average of $12.86. The firm’s market cap is $2.07 billion. Allscripts Healthcare Solutions has a 12 month low of $9.80 and a 12 month high of $15.78.
Allscripts Healthcare Solutions (NASDAQ:MDRX) last released its earnings results on Thursday, November 3rd. The company reported $0.14 earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.15 by $0.01. The firm earned $392.40 million during the quarter, compared to the consensus estimate of $414.92 million. Allscripts Healthcare Solutions had a positive return on equity of 5.79% and a negative net margin of 0.14%. The business’s quarterly revenue was up 10.7% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.13 EPS. Equities research analysts predict that Allscripts Healthcare Solutions will post $0.56 earnings per share for the current year.